Branded Generics Market Growth Accelerates: Strategic Forecast Predicts $588.37 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Branded Generics Industry Market Size Be by 2025?
The branded generics industry has seen significant growth over the recent years. The industry, which is anticipated to rise from $363.49 billion in 2024 to $393.5 billion in 2025, will experience a compound annual growth rate (CAGR) of 8.3%. This remarkable growth during the historic period can be accredited to factors such as cost effectiveness and affordability, patent expirations, expansion and accessibility of the market, as well as support from government policies and healthcare reforms.

What's the Long-Term Growth Forecast for the Branded Generics Market Size Through 2029?
The market size for branded generics is forecasted to experience robust expansion in the years ahead, ballooning to "$588.37 billion by 2029" with a compound annual growth rate (CAGR) of 10.6%. This predicted surge over the forecast period can be linked to the increasing demand for generic biologics, the escalation of chronic diseases, growing markets, and emphasis on biosimilars. Some of the key trends for the forecast period comprise strategic alliances and collaborations, technological progress, focus on chronic ailments, market amalgamation, and a patient-centric approach.

View the full report here:
https://www.thebusinessresearchcompany.com/report/branded-generics-global-market-report

What Are the Key Growth Drivers Fueling the Branded Generics Market Expansion?
Growth in the branded generics market is largely driven by the rising occurrence of chronic diseases. Chronic diseases are enduring illnesses that aren't typically cured but can be managed and treated. Lifestyle habits such as excessive tobacco and alcohol consumption, poor diet, and physical inactivity contribute to their rise. Globally, consumers are favoring branded generics for treating chronic ailments due to their cheaper cost compared to conventional medications. As per the World Health Organization's 2022 Highlights published in September 2022, this Switzerland-based health organization reported 41 million deaths, or 74% of total deaths, as a result of noncommunicable diseases or chronic illnesses each year worldwide. Hence, the growing instances of chronic diseases are anticipated to escalate the demand for branded generics in the projected timeframe.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=7186&type=smp

What Are the Key Trends Driving Branded Generics Market Growth?
Among the major trends within the branded generics sector, the formation of strategic alliances holds a significant place. Branded generics companies are increasingly forging partnerships with related companies, leveraging each other's resources while breaking into new markets. To illustrate, in September 2024, Biocon Ltd., a pharmaceutical company hailing from India, formed an alliance with Tabuk Pharmaceuticals. Biocon is charged with the development and production of GLP-1 products, ensuring the delivery of top-tier biopharmaceuticals aimed at diabetes treatment. Meanwhile, Tabuk Pharmaceuticals will obtain marketing authorization rights and will oversee the registration, importation, and promotion of these products mainly in Saudi Arabia, and the Middle East. The partnership contract also encompasses potential future expansion to other GLP products, thus broadening the scope of diabetes therapies. The purpose of this alliance is to offer unparalleled healthcare solutions, promoting the welfare of patients in Saudi Arabia and its surroundings. This is in line with the commitment of both firms to enhance healthcare accessibility. Tabuk Pharmaceuticals, based in Saudi Arabia, markets both branded and generic pharmaceutical products.

How Is the Branded Generics Market Segmented?
The branded generics market covered in this report is segmented -

1) By Drug Class: Alkylating Agents, Antimetabolites, Hormones, Anti-Hypertensive, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptics, Other Drugs
2) By Route Of Administration: Topical, Oral, Parenteral, Other Routes Of Administration
3) By Application: Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics And Anti-inflammatory, Other Applications

Subsegments:
1) By Alkylating Agents: Nitrogen Mustards, Ethylene Imine Compounds
2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues
3) By Hormones: Corticosteroids, Thyroid Hormones
4) By Anti-Hypertensive: ACE Inhibitors, Beta Blockers, Calcium Channel Blockers
5) By Lipid Lowering Drugs: Statins, Fibrates
6) By Anti-Depressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)
7) By Anti-Psychotics: Atypical Antipsychotics, Typical Antipsychotics
8) By Anti-Epileptics: Sodium Channel Blockers, GABAergic Drugs
9) By Other Drugs: Analgesics, Antibiotics, Antivirals

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=7186&type=smp

Which Companies Are Leading the Charge in Branded Generics Market Innovation?
Major companies operating in the branded generics market include Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Mylan N.V., Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Apotex Inc., Aspen Pharmacare Holdings Limited, Endo International plc, Towa Pharmaceutical Co. Ltd., Mankind Pharma, Glenmark Pharmaceuticals, Par Pharmaceuticals Inc., Unichem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Wockhardt, Intas Pharmaceuticals Ltd., Novartis International AG, Novo Nordisk A/S, Zydus Lifesciences Ltd.

Which Regions Are Leading the Global Branded Generics Market in Revenue?
North America was the largest region in the branded generics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the branded generics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7186

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert: Saumya Sahay: Americas +1 310-496-7795: Asia +44 7882 955267 & +91 8897263534: Europe +44 7882 955267: Email: saumyas@tbrc.info: The Business Research Company - www.thebusinessresearchcompany.com: Follow Us On: LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.